Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon alfa-2a + influenza vaccine trivalent inactivated
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Vaccines & Immunotherapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
interferon alfa-2a + influenza vaccine trivalent inactivated is a combination therapy investigated by the M.D. Anderson Cancer Center to improve the efficacy of seasonal influenza vaccination in patients with Chronic Lymphocytic Leukemia (CLL). The regimen involves the co-administration of a licensed trivalent inactivated influenza vaccine (TIV) with recombinant interferon alfa-2a, either in its standard form (Roferon-A) or its pegylated form (Pegasys). Interferon alfa-2a serves as a cytokine adjuvant that binds to the interferon alpha/beta receptors (IFNAR1 and IFNAR2), stimulating the innate and adaptive immune systems to produce a more robust antibody response against the influenza virus hemagglutinin antigens, which is typically diminished in CLL patients due to their underlying malignancy.
- Brand names
- Pegasys
- Other names
- IFNαPEGrIFN-αTIVTrivalent Inactivated Influenza Vaccine
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)HA (Hemagglutinin)IFNAR1 (Interferon alpha/beta receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on interferon alfa-2a + influenza vaccine trivalent inactivated.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon alfa-2a + influenza vaccine trivalent inactivated.